BeiGene

~50% of CLL patients have high-risk features that may limit the effectiveness of some treatments. Biomarker testing helps guide the best care plan.     Learn more at https://ow.ly/5kws50VbW1s.     #TestBeforeTreat #CLL 

#News for #Investors and #Media: This week, the journal Advances in Therapy published two new manuscripts about our PD-1 inhibitor in patients with PD-L1 expression ≥1% in gastric cancers and esophageal squamous cell carcinoma. Highlighting our commitment to furthering the science of cancer by more fully exploring the role of PD-L1 expression, these publications contribute to the body of evidence focused on the majority of patients whose PD-L1 levels are ≥1%. Read the manuscripts here: https://lnkd.in/edzf44md https://lnkd.in/eccaGVTn #Oncology #ESCC

“Everyone is working for the same goal.” We’re committed to making a lasting impact on the world, driven by a sense of urgency and agility to follow the science and deliver for patients. Meet Inca Hagenforff, Associate Director, Customer Engagement, who reflects on her journey as one of our first team members. Over the years, she’s seen our company grow both in team size and through our expanding pipeline. Watch her video and hear about the fulfillment she feels knowing her work has a meaningful impact on patients’ lives. Interested in exploring career opportunities with us? Visit https://ow.ly/tyke50VcRC9. #Oncology #PatientsFirst

What if we could eliminate selected disease-causing proteins? Targeted degraders aim to do just that. Our chimeric degradation activation compounds (CDACs) are designed to eliminate target proteins, potentially side-stepping resistance. Visit https://ow.ly/Ye4850VaAiQ to see how we’re developing our investigational BTK-targeted CDAC.

At the Leerink Partners Global Biopharma Conference in Miami yesterday, our CFO, Aaron Rosenberg, CFA, CMO of Solid Tumors, Mark Lanasa, and GM of North America, Matthew Shaulis, participated in a fireside chat with Senior Biotechnology Analyst Andrew Berens, MD, MBA.   During the discussion, they provided key updates on our global milestones and leadership in #oncology, including the recent U.S. FDA approval of our PD-1 inhibitor in its third indication within a year, the commercial success of our BTK inhibitor, and highlights from our promising pipeline assets.   Missed the session or would like to revisit the discussion? Access the webcast in the "Events & Presentations" section of our investor website at ir.beigene.com.

Throughout my career, I’ve always sought to answer one fundamental question: why do we do what we do?  I recently spoke with pharmaphorum to reflect on my career journey—on the mission that drives us at BeiGene, the importance of making innovative medicines accessible faster and at a broader scale, and the role of leadership in fostering diverse and collaborative teams.    From the power of AI in early cancer detection to the challenges of global treatment access also affecting Europe, the future of oncology is evolving rapidly. But at the heart of it all, patients must remain our focus.     Read the full interview here: 12 Questions with Giancarlo Benelli (https://lnkd.in/dZkcXVPd)   #Leadership #Oncology #cancerhasnoborders

Wrapping up our conversation, John V. Oyler—our Co-Founder, Chairman, and CEO—joins the podcast to share his journey as an entrepreneur and the story behind founding our company 15 years ago. Tune in as he reflects on the challenges, breakthroughs, and invaluable lessons learned while building a global #oncology powerhouse.   Spotify: https://ow.ly/xehY50Vf75l Apple: https://ow.ly/5lbb50Vf75n YouTube: https://ow.ly/WRib50Vf75o

Today at the R&D Leadership Summit, our Co-Founder, Chairman, and CEO, John V. Oyler, joined CEOs from leading pharma and biotech companies to discuss critical issues shaping R&D decision-making. During the panel, 'Assessing the Political and Regulatory Landscape Post-2024 Presidential Election,' John and fellow panelists explored government policy trends and their impact on drug innovation, pricing, reimbursement, and patient access.   We’re dedicated to advancing R&D productivity in these dynamic times, as we believe accelerating the development of innovative medicines is essential to meeting the evolving needs of patients worldwide. Ron Cohen, M.D. Josh Gottheimer John F. Crowley

We’re proud to partner with the ATOM Coalition, led by Union for International Cancer Control (UICC), in its mission to revolutionize cancer treatment access in low- and middle-income countries. A recent Lancet Oncology article highlights the innovative, sustainable strategies the ATOM Coalition is developing to overcome critical barriers in #oncology care. Check it out here: https://lnkd.in/e2SUFSiE   From innovative licensing and donation programs to enhanced supply chains and procurement models, the ATOM Coalition is pioneering solutions that make impactful medicines more available and affordable. By uniting efforts across civil society, public, and private sectors, we can create lasting, sustainable access to cancer treatment where it’s needed most.

I was honored to share the stage at #SXSW with Pat Garcia-Gonzalez and Jeff Allen to discuss the importance of forging collaborations to help broaden access to life-saving medicines around the world. I started my professional career as a clinician taking care of patients with cancer and saw first-hand the unmet needs that existed with the treatment options available at that time. I decided to focus on drug development so I could make a greater impact and potentially change both the trajectory of disease and patient lives. But I know that the clinical research at BeiGene is only the initial part of the solution and that if our medicines don’t reach patients, then our efforts are in vain. Thanks to partners such as Pat and Jeff’s organizations, we’re working to ensure access to care isn’t determined by where you live.